<DOC>
	<DOCNO>NCT02251197</DOCNO>
	<brief_summary>The objective study ass safety , tolerability pharmacokinetic characteristic BIII 890 intravenous infusion acute ischemic stroke patient .</brief_summary>
	<brief_title>Safety Tolerability BIII 890 Patients With Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<criteria>Male female patient age 18 year Patients acute onset focal neurological deficit secondary lesion presume ischemic etiology involve carotid and/or vertebrobasilar artery territory Onset symptom within 24 hour prior initiation administration study drug . If patient awaken sleep deficit , time onset consider last time he/she normal Stroke symptom present least 1 hour still present randomisation . Symptoms must distinguishable episode generalise ischemia ( i.e . syncope ) , seizure , migraine hypoglycaemic disorder Patient willing participate voluntarily sign write patient inform consent . Informed consent obtain Patient ( subject 's representative relative , depend local regulation ) accord Good Clinical Practice regulatory legal requirement participate country . Patients unable sign able understand mean participation study may give oral witness informed consent . These patient make clear undoubtfully wiling participate voluntarily must able understand Explanation content Information sheet Patient 's life expectancy least 30 day ( investigator 's judgement ) Presence minor stroke symptom characterise NIH score &lt; 4 time randomisation Severe obtundation define NIH Stroke Scale score ≥ 2 use Level Consciousness category ; include coma severe stupor Any patient concurrent , severe neurological disease Dementia , multiinfarct dementia Multiple sclerosis Previous stroke residual deficit ( i.e . prestroke modify Rankin Scale ( mRS ) must ≤ 1 ) . Tomographic clinical evidence brain stem infarct , intracranial haemorrhage , primary metastatic brain tumour , meningioma , space occupy lesion ( e.g. , subdural epidural haematoma ) Patient history seizure relate stroke diagnosis , except seizure secondary fever childhood Any patient concurrent mental deficit ( e.g. , AXISI psychiatric disorder define Diagnostic Statistical Manual ( DSM ) IV criterion : schizophrenia , mood disorder ( mania major depression ) , psychotic/delusional disorder , recent history ( 6 month ) current evidence alcohol recreational drug abuse Baseline blood glucose value 2.75 mmol/l ( hypoglycaemia ) 22.0 mmol/l ( hyperglycaemia ) Sustained supine hypertension baseline period , prior randomisation , define two reading 30 minute apart systolic blood pressure ≥ 220 mmHg and/or diastolic blood pressure ≥ 120 mmHg ; and/or clinical diagnosis malignant hypertensive crisis accompany sign symptom ( e.g . nausea , vomit , obtundation , etc . ) complication ( e.g . papilledema , retinal haemorrhage , hematuria , congestive heart failure ) Patients known history orthostatic hypotension , faint spell blackout . Hypotension define systolic blood pressure ≤ 90 mmHg diastolic blood pressure ≤ 50 mmHg Patients currently oral anticoagulant . A time window least two day observe treatment administer stop begin trial Known history serious , advanced , unstable terminal illness opinion clinical investigator may interfere trial confound result pose additional risk : cardiogenic shock , congestive heart failure ( NYHA Class IIIIV ) , acute myocardial infarction history myocardial infarction within past three month , unstable angina renal failure , severe hepatic disease , unstable gastrointestinal , pulmonary , metabolic , immunological , hormonal disorder cancer ( except local skin cancer , e.g . : basal squamous carcinoma ) HIV+ Females lactate pregnant ( determined pregnancy test screening ) childbearing potential Current recent ( within 3 month ) participation another investigational drug protocol Patient follow 30 day ( accord judgement investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>